A gemcitabine intravesical releasing system ... alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer ...

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free following ...